CureVac points to variant profile in pivotal miss for mRNA vaccine

It's not clear yet if structural differences, dosing levels or an evolving variant profile in the community is to blame for the first pivotal miss of a COVID-19 vaccine: CVnCoV from Cure Vac.

CureVac N.V. (NASDAQ:CVAC) said Wednesday that an interim analysis of its Phase IIb/III HERALD study showed 47% efficacy for its mRNA vaccine CVnCoV, failing to meet pre-specified success criteria. ...